Quantcast

Latest glioblastoma Stories

2014-09-17 08:28:28

ICT-107 Phase II Update Selected for Oral Presentation at Society for Neuro-Oncology Meeting in November; ICT-121 and ICT-140 Programs on Track LOS ANGELES, Sept. 17, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) provides a corporate update on its plans to advance ICT-107 to a registrational phase III program in patients with newly diagnosed glioblastoma (GBM), and on its portfolio of dendritic cell-based vaccines: ICT-121 for patients...

2014-08-12 08:30:58

SAN FRANCISCO, Aug. 12, 2014 /PRNewswire-iReach/ -- OncoSynergy announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for the investigational drug candidate OS2966, a neutralizing anti-CD29 monoclonal antibody, for the treatment of glioblastoma, the most common and deadliest primary adult brain tumor. (Photo: http://photos.prnewswire.com/prnh/20140811/135194) OS2966 is a first in class therapeutic being investigated in...

2014-07-07 10:11:17

McGill University Scientists at the Montreal Neurological Institute and Hospital, McGill University and McGill University Health Centre have shown that a member of the protein family known as SUMO (small ubiquitin-like modifier) is a key to why tumour cells multiply uncontrollably, especially in the case of glioblastoma. The SUMO family proteins modify other proteins and the SUMOylation of proteins are critical for many cellular processes. Identifying SUMO’s role in the cancer cell...

2014-06-15 14:59:20

Broad Institute of MIT and Harvard Cellular makeup of glioblastoma more diverse than previously thought Scientists from the Broad Institute and Massachusetts General Hospital (MGH) have conducted a first-of-its-kind study that characterizes the cellular diversity within glioblastoma tumors from patients. The study, which looked at the expression of thousands of genes in individual cells from patient tumors, revealed that the cellular makeup of each tumor is more heterogeneous than...

2014-06-01 08:20:27

Pre-specified MGMT and HLA Subgroup Analyses Show Potentially Clinically Meaningful Survival Advantages for ICT-107 Treated Patients LOS ANGELES, June 1, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical...

2014-05-30 08:24:56

- Results from Phase I study of investigational oncology compound ABT-414 in patients with recurrent or unresectable glioblastoma multiforme, an aggressive type of brain cancer NORTH CHICAGO, Ill., May 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one...

2014-05-29 04:21:52

ROCKLAND, Massachusetts, May 29, 2014 /PRNewswire/ -- ASCO abstract #: Anti-PD-L1: 3064; c-Met: 2521, TPS4151, TPS8121; tecemotide: TPS3658, TPS7608; TH-302: 8534, 2029; further pipeline: 3551, TPS9107, 5030, 2050, e13552 - Robust pipeline reflects commitment to innovation in oncology and immuno-oncology - Data from nine EMD Serono pipeline products across oncology and immuno-oncology to be presented, including anti-PD-L1, c-Met...

2014-05-19 08:28:02

A registry of 457 recurrent glioblastoma patients shows that patients treated commercially with NovoTTF Therapy in 2012 and 2013 achieved the longest median overall survival yet shown in non-experimental use for patients with recurrent glioblastoma NEW YORK, May 19, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that an analysis of the efficacy and safety data from its U.S. patient registry will be published as part of the 50(th) meeting of the...

2014-05-08 12:29:01

#TuneIn2GBM Social Media Campaign to Raise Awareness to Help Fight a Deadly Form of Brain Cancer PORTSMOUTH, N.H., May 8, 2014 /PRNewswire/ -- For the second consecutive year, Novocure is sponsoring its Tune-In to GBM campaign, a public call to action to "Tune-In" to glioblastoma (GBM) during National Brain Cancer Awareness Month this May. After the success of last year's inaugural campaign, Novocure is excited to combine forces with the Cancer Support Community, the Chris Elliott...

2014-05-01 08:36:12

Glioblastoma is the most common form of primary brain cancer VANCOUVER, Canada and MENLO PARK, Calif., May 1, 2014 /PRNewswire/ -- Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar Pharma" or "DelMar") discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related